Drugs / Fosifloxuridine Nafalbenamide
Trials 4 · a red edge is where a trial was stopped
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 11 trial | ||||||
| Phase 1 | NCT02723240 | Jan 2016 → Feb 2020 | cancer | University of Oxford | Completed | No outcome recorded |
| Phase 1/22 trials | ||||||
| Phase 1/2 | NCT05714553 | Mar 2023 → May 2025 | cancer of unknown primary site, carcinoma of esophagus, classic Hodgkin lymphoma, colorectal cancer +11 | NuCana plc | Terminated | No outcome recorded |
| Phase 1/2 | NCT03428958 | Oct 2018 → Mar 2024 | colorectal carcinoma | NuCana plc | Completed | No outcome recorded |
| Phase 21 trial | ||||||
| Phase 2 | NCT05678257 | Apr 2023 → Aug 2024 | colorectal adenocarcinoma | NuCana plc | Terminated | No outcome recorded |
Evidence & citations 9 cited values
Every value below carries the sentence it was read from. 6 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | Fosifloxuridine Nafalbenamide | ClinicalTrials.gov intervention name — accepted as the source's own label NCT05714553 ↗ |
| Known as | CPF-373 | ChEMBL registry synonym — accepted as the source's own label CHEMBL2181367 ↗ |
| Known as | Fosifloxuridina nafalbenamida | ChEMBL registry synonym — accepted as the source's own label CHEMBL2181367 ↗ |
| Known as | NUC-3073 | ChEMBL registry synonym — accepted as the source's own label CHEMBL2181367 ↗ |
| Known as | NUC-3373 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT03428958 ↗ |
| Action | Inhibit | “NUC-3373, a targeted thymidylate synthase inhibitor” PMID 38566164 ↗ Apr 2024 |
| Modality | Small molecule | “NUC-3373 (a pyrimidine nucleotide analogue)” NCT02723240 ↗ |
| Route | Intravenous | “administered weekly or fortnightly as an I.V. (intravenous) infusion” NCT02723240 ↗ |
| Target | TYMS | “NUC-3373, a targeted thymidylate synthase inhibitor” PMID 38566164 ↗ Apr 2024 |